Charles Moussallem, MD
Nephrology · Fort Smith, ARNPI 1023318334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Amgen at 25.1% of the total.
Across 261 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$674
- Travere Therapeutics, Inc.$413
- OPKO Pharmaceuticals, LLC$354
- Fresenius USA Marketing, Inc.$346
- Novartis$317
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,40698%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 68 | $1,380 |
| AstraZeneca(2 entities) | 40 | $674 |
| Travere Therapeutics, Inc. | 20 | $413 |
| OPKO Pharmaceuticals, LLC | 19 | $354 |
| Fresenius USA Marketing, Inc. | 11 | $346 |
| Novartis | 12 | $317 |
| GSK | 10 | $277 |
| Vifor Pharma, Inc. | 12 | $238 |
| Novo Nordisk | 10 | $215 |
| Aurinia Pharma U.S., Inc. | 8 | $197 |
| Bayer | 10 | $190 |
| Ardelyx, Inc. | 7 | $186 |
| Calliditas Therapeutics US Inc. | 5 | $127 |
| ANI Pharmaceuticals, Inc. | 4 | $98 |
| Boehringer Ingelheim | 6 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Johnson & Johnson | 2 | $49 |
| Akebia Therapeutics Inc | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Cormedix Inc. | 2 | $31 |
| Vantive US Healthcare LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Nxstage Medical, Inc. | 1 | $16 |
How this compares
$5,494 in reported general payments places this provider in the 80th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 136 | $129,017 |
| JardianceEmpagliflozin | 108 | $98,238 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $21,757 |
| Calcium Acetate | 95 | $5,220 |
| Sevelamer Carbonate | 28 | $4,743 |
| Potassium Chloride | 76 | $1,833 |
| Torsemide | 68 | $1,664 |
| Furosemide | 246 | $1,151 |
| Tamsulosin Hcl | 58 | $845 |
| Amlodipine Besylate | 94 | $644 |
| Labetalol Hcl | 12 | $565 |
| Metolazone | 39 | $528 |
| Allopurinol | 60 | $489 |
| Clonidine | 13 | $477 |
| Gentamicin Sulfate | 15 | $454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $674 | $150,775157 claims |
| Boehringer IngelheimJardiance | $95 | $98,238108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 85 nephrology providers in Arkansas.
Other nephrology in Fort Smith
- Hania Al-ShahrouriFort Smith$8K
- James HenryFort Smith$5K
- James BrutonFort Smith$5K
- Muhammad Zatmar KhanFort Smith$2K
- Divine RibakareFort Smith$2K
- Alex Eduardo Calderon RodriguezFort Smith$1K
- Andres Pirela AraqueFort Smith$558
- Dumitru RotaruFort Smith$553
- Drew HeipleRussellville$236K
- Luis JuncosLittle Rock$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.